Rubius resorts to layoffs and abandons its lead programs as its survival strategy

Aayushi Pratap

News Reporter

Amber Tong

Four years ago, Cambridge-based Rubius Therapeutics was having the time of its life. The company, which makes engineered red cells, was raking in ample cash …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rubius resorts to layoffs and abandons its lead programs as its survival strategy

Aayushi Pratap

News Reporter

Amber Tong

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Sofinnova outlines $550M fund after IPOs and M&A deals

Ru­bius re­sorts to lay­offs and aban­dons its lead pro­grams as its sur­vival strat­e­gy

News Reporter

Sign up to read this article for free.

more like this

Rubius resorts to layoffs and abandons its lead programs as its survival strategy